Control Bionics Ltd (CBL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Control Bionics Ltd (CBL) has a cash flow conversion efficiency ratio of -0.288x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.22 Million ≈ $-1.57 Million USD) by net assets (AU$7.73 Million ≈ $5.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Control Bionics Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Control Bionics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CBL current and long-term liabilities for a breakdown of total debt and financial obligations.
Control Bionics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Control Bionics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aelis Farma SA
PA:AELIS
|
-0.635x |
|
Daesung Microbiological Labs. Co. Ltd
KQ:036480
|
-0.018x |
|
Keller Group PLC
LSE:KLR
|
0.077x |
|
Hubei Geoway Investment Co Ltd
SHG:600462
|
0.893x |
|
Evoke Pharma Inc
NASDAQ:EVOK
|
-0.155x |
|
Vincit Group Oyj
HE:VINCIT
|
-0.010x |
|
BIT Mining Limited
NYSE:BTCM
|
-0.167x |
|
Salee Colour Public Company Limited
BK:COLOR
|
0.017x |
Annual Cash Flow Conversion Efficiency for Control Bionics Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Control Bionics Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Control Bionics Ltd (CBL) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$5.51 Million ≈ $3.90 Million |
AU$-4.27 Million ≈ $-3.02 Million |
-0.775x | +1.11% |
| 2023-12-31 | AU$6.27 Million ≈ $4.43 Million |
AU$-4.91 Million ≈ $-3.48 Million |
-0.784x | -23.18% |
| 2022-12-31 | AU$7.12 Million ≈ $5.04 Million |
AU$-4.53 Million ≈ $-3.20 Million |
-0.636x | -10.15% |
| 2021-12-31 | AU$11.92 Million ≈ $8.44 Million |
AU$-6.89 Million ≈ $-4.87 Million |
-0.578x | -148.41% |
| 2020-12-31 | AU$17.16 Million ≈ $12.14 Million |
AU$-3.99 Million ≈ $-2.82 Million |
-0.233x | -441.59% |
| 2019-12-31 | AU$20.13 Million ≈ $14.24 Million |
AU$-864.05K ≈ $-611.37K |
-0.043x | +88.85% |
| 2018-12-31 | AU$5.05 Million ≈ $3.58 Million |
AU$-1.95 Million ≈ $-1.38 Million |
-0.385x | -141.49% |
| 2017-12-31 | AU$6.09 Million ≈ $4.31 Million |
AU$-970.84K ≈ $-686.93K |
-0.159x | -- |
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more